A Phase 3 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 21st largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 14th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2007.
This study's enrollment of 124 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 17th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2007, is one of 19 in phase 3, and was the 15th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects are not permitted to enroll in the trial if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
Drug: Rotigotine
Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
Also known as: Neupro
Change in Pulse Rate (Supine, After 1 Minute)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Systolic Blood Pressure (Supine, After 1 Minute)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Diastolic Blood Pressure (Supine, After 1 Minute)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Pulse Rate (Supine, After 5 Minutes)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Systolic Blood Pressure (Supine, After 5 Minutes)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 Days
Change in Diastolic Blood Pressure (Supine, After 5 Minutes)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Pulse Rate (Standing, After 1 Minute)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Systolic Blood Pressure (Standing, After 1 Minute)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Diastolic Blood Pressure (Standing, After 1 Minute)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Pulse Rate (Standing, After 3 Minutes)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Systolic Blood Pressure (Standing, After 3 Minutes)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Diastolic Blood Pressure (Standing, After 3 Minutes)
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Heart Rate
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in PR Interval
The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex). Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in QRS Duration
The QRS duration represents the time it takes for ventricular depolarization to occur. Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in QT Interval
The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)
The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Percentage of Basophilic Granulocytes in White Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Hematocrit
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Hemoglobin
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Percentage of Lymphocytes in White Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Percentage of Monocytes in White Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Platelet Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Red Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in White Blood Cell Count
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Albumin
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Alkaline Phosphatase
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Blood Urea Nitrogen
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Calcium
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Chloride
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Creatinine
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Gamma-Glutamyltransferase
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Glucose
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Inorganic Phosphate
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Potassium
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Serum Glutamic Oxaloacetic Transaminase
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Glutamic Pyruvic Transaminase
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Sodium
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Total Bilirubin
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Total Protein
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Uric Acid
Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception'
Time frame: 28 days
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other'
Time frame: 28 days
Completion of Trial From Baseline to End of Treatment
Time frame: Baseline, 28 days
Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment
Time frame: Baseline, 28 days
Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)
Time frame: Baseline, 2 days
Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period
Time frame: Baseline, 56 days
Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)
Time frame: Baseline, 2 days
Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period
Time frame: Baseline, 56 days
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment
The PDSS is a scale to assess sleep and nocturnal disability in Parkinson's disease. Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment
The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment
The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson's disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Severity of Parkinson's Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Clinical Global Impression (CGI) Item 2 Score
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)
Time frame: 28 days
Clinical Global Impression (CGI) Item 3.1
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)
Time frame: 28 days
Clinical Global Impression (CGI) Item 3.2
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)
Time frame: 28 days
Patient Global Impression (PGI) Item 1 Score
The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)
Time frame: 28 days
Patient Global Impression (PGI) Item 2
The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)
Time frame: 28 days
Patient Global Impression (PGI) Item 3
The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)
Time frame: 28 days
Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment
The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.
Time frame: Baseline, 28 days
Patient Treatment Preference Scale Question 1
Have you used pharmaceutical treatments for your Parkinson's disease before the study?
Time frame: 28 days
Patient Treatment Preference Scale Question 2
Why did you decide to enter this study?
Time frame: 28 days
Patient Treatment Preference Scale Question 3
In comparing the patch and previous oral treatments for Parkinson's disease, how satisfied have you been with oral medication / patch?
Time frame: 28 days
Patient Treatment Preference Scale Question 4
I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson's disease.
Time frame: 28 days
Patient Treatment Preference Scale Question 5
I would prefer applying one 40cm\*\*2 patch over applying two 20cm\*\*2 patches for treatment of my Parkinson's disease.
Time frame: 28 days
Patient Treatment Preference Scale Question 6
What aspects do you like the most about the patch?
Time frame: 28 days
Patient Treatment Preference Scale Question 7
What aspects do you like the least about the patch? Check all that apply.
Time frame: 28 days
124 patients were screened. 5 patients were run-in failures and 3 patients were screen failures. 116 patients started treatment, i.e. were included into the Safety Set. 114 patients were included into the Full Analysis Set. 99 patients completed the treatment period. 2 patients withdrew after the treatment period. 97 patients completed the study.
| Milestone | Rotigotine |
|---|---|
| Started | 124 |
| Start of treatment - safety set | 116 |
| Full analysis set | 114 |
| Treatment period completed | 99 |
| Completed | 97 |
| Not completed | 27 |
| Withdrew: Adverse event | 13 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Run-in failure | 5 |
| Withdrew: Screen failure | 3 |
Change = 28 day value minus baseline value.
| beats per minute | Rotigotine |
|---|---|
| Change in Pulse Rate (Supine, After 1 Minute) | 2.0 ± 9.4 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Systolic Blood Pressure (Supine, After 1 Minute) | 5.7 ± 14.1 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Diastolic Blood Pressure (Supine, After 1 Minute) | 1.7 ± 9.6 |
Change = 28 day value minus baseline value.
| beats per minute | Rotigotine |
|---|---|
| Change in Pulse Rate (Supine, After 5 Minutes) | 1.8 ± 8.8 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Systolic Blood Pressure (Supine, After 5 Minutes) | 2.6 ± 13.1 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Diastolic Blood Pressure (Supine, After 5 Minutes) | 0.6 ± 9.8 |
Change = 28 day value minus baseline value.
| beats per minute | Rotigotine |
|---|---|
| Change in Pulse Rate (Standing, After 1 Minute) | 1.7 ± 11.8 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Systolic Blood Pressure (Standing, After 1 Minute) | -0.2 ± 12.7 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Diastolic Blood Pressure (Standing, After 1 Minute) | 0.8 ± 10.1 |
Change = 28 day value minus baseline value.
| beats per minute | Rotigotine |
|---|---|
| Change in Pulse Rate (Standing, After 3 Minutes) | 0.8 ± 11.1 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Systolic Blood Pressure (Standing, After 3 Minutes) | 2.0 ± 12.4 |
Change = 28 day value minus baseline value.
| mmHg | Rotigotine |
|---|---|
| Change in Diastolic Blood Pressure (Standing, After 3 Minutes) | 0.8 ± 9.1 |
Change = 28 day value minus baseline value.
| beats per minute | Rotigotine |
|---|---|
| Change in Heart Rate | 0.5 ± 8.7 |
The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex). Change = 28 day value minus baseline value.
| msec | Rotigotine |
|---|---|
| Change in PR Interval | -0.0 ± 14.6 |
The QRS duration represents the time it takes for ventricular depolarization to occur. Change = 28 day value minus baseline value.
| msec | Rotigotine |
|---|---|
| Change in QRS Duration | -1.2 ± 6.3 |
The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.
| msec | Rotigotine |
|---|---|
| Change in QT Interval | -1.7 ± 30.5 |
The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.
| msec | Rotigotine |
|---|---|
| Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB) | 0.5 ± 23.1 |
Change = 28 day value minus baseline value.
| Percentage of white blood cell count | Rotigotine |
|---|---|
| Change in Percentage of Basophilic Granulocytes in White Blood Cell Count | 0.01 ± 0.33 |
Change = 28 day value minus baseline value.
| Percentage of white blood cell count | Rotigotine |
|---|---|
| Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count | -0.11 ± 1.71 |
Change = 28 day value minus baseline value.
| l/l*100 | Rotigotine |
|---|---|
| Change in Hematocrit | 0.09 ± 1.71 |
Change = 28 day value minus baseline value.
| g/l | Rotigotine |
|---|---|
| Change in Hemoglobin | 0.8 ± 5.6 |
Change = 28 day value minus baseline value.
| Percentage of white blood cell count | Rotigotine |
|---|---|
| Change in Percentage of Lymphocytes in White Blood Cell Count | 0.73 ± 7.12 |
Change = 28 day value minus baseline value.
| Percentage of white blood cell count | Rotigotine |
|---|---|
| Change in Percentage of Monocytes in White Blood Cell Count | 0.96 ± 8.41 |
Change = 28 day value minus baseline value.
| Percentage of white blood cell count | Rotigotine |
|---|---|
| Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count | -0.40 ± 12.69 |
Change = 28 day value minus baseline value.
| Giga/l | Rotigotine |
|---|---|
| Change in Platelet Count | 2.6 ± 29.5 |
Change = 28 day value minus baseline value.
| Tera/l | Rotigotine |
|---|---|
| Change in Red Blood Cell Count | 0.023 ± 0.213 |
Change = 28 day value minus baseline value.
| Giga/l | Rotigotine |
|---|---|
| Change in White Blood Cell Count | -0.045 ± 3.538 |
Change = 28 day value minus baseline value.
| g/l | Rotigotine |
|---|---|
| Change in Albumin | -0.5 ± 2.1 |
Change = 28 day value minus baseline value.
| Units/l | Rotigotine |
|---|---|
| Change in Alkaline Phosphatase | -1.4 ± 16.9 |
Change = 28 day value minus baseline value.
| mmol/l | Rotigotine |
|---|---|
| Change in Blood Urea Nitrogen | -0.24 ± 1.75 |
Change = 28 day value minus baseline value.
| mg/dl | Rotigotine |
|---|---|
| Change in Calcium | -0.05 ± 0.30 |
Change = 28 day value minus baseline value.
| mmol/l | Rotigotine |
|---|---|
| Change in Chloride | -0.4 ± 2.5 |
Change = 28 day value minus baseline value.
| mg/dl | Rotigotine |
|---|---|
| Change in Creatinine | -0.004 ± 0.101 |
Change = 28 day value minus baseline value.
| Units/l | Rotigotine |
|---|---|
| Change in Gamma-Glutamyltransferase | -0.1 ± 7.5 |
Change = 28 day value minus baseline value.
| mg/dl | Rotigotine |
|---|---|
| Change in Glucose | -0.2 ± 30.0 |
Change = 28 day value minus baseline value.
| mg/dl | Rotigotine |
|---|---|
| Change in Inorganic Phosphate | -0.03 ± 0.52 |
Change = 28 day value minus baseline value.
| mmol/l | Rotigotine |
|---|---|
| Change in Potassium | 0.08 ± 0.35 |
Change = 28 day value minus baseline value.
| Units/l | Rotigotine |
|---|---|
| Change in Serum Glutamic Oxaloacetic Transaminase | -0.1 ± 7.9 |
Change = 28 day value minus baseline value.
| Units/l | Rotigotine |
|---|---|
| Change in Glutamic Pyruvic Transaminase | -0.2 ± 15.6 |
Change = 28 day value minus baseline value.
| mmol/l | Rotigotine |
|---|---|
| Change in Sodium | -0.6 ± 2.2 |
Change = 28 day value minus baseline value.
| mg/dl | Rotigotine |
|---|---|
| Change in Total Bilirubin | 0.079 ± 1.133 |
Change = 28 day value minus baseline value.
| g/dl | Rotigotine |
|---|---|
| Change in Total Protein | -0.09 ± 0.36 |
Change = 28 day value minus baseline value.
| µmol/l | Rotigotine |
|---|---|
| Change in Uric Acid | -3.80 ± 35.62 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological' | 1 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal' | 1 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait' | 1 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements' | 1 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception' | 0 |
| participants | Rotigotine |
|---|---|
| Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other' | 0 |
| participants | Rotigotine |
|---|---|
| Completion of Trial From Baseline to End of Treatment | 99 |
| participants | Rotigotine |
|---|---|
| Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment | 88 |
| participants | Rotigotine |
|---|---|
| Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs) | 0 |
| participants | Rotigotine |
|---|---|
| Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period | 9 |
| participants | Rotigotine |
|---|---|
| Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs) | 1 |
| participants | Rotigotine |
|---|---|
| Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period | 1 |
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment | -0.5 ± 1.2 |
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment | -0.9 ± 3.3 |
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment | -1.9 ± 5.9 |
The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment | -0.4 ± 1.8 |
The PDSS is a scale to assess sleep and nocturnal disability in Parkinson's disease. Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment | -0.8 ± 7.3 |
The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment | -0.2 ± 3.2 |
The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson's disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment | -7.9 ± 19.8 |
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Severity of Parkinson's Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment | -0.0 ± 0.6 |
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)
| score on scale | Rotigotine |
|---|---|
| Clinical Global Impression (CGI) Item 2 Score | 3.6 ± 1.0 |
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)
| participants | Rotigotine |
|---|---|
| Marked | 3 |
| Moderate | 20 |
| Minimal | 36 |
| Unchanged or Worse | 54 |
| Not Assessed | 1 |
The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)
| participants | Rotigotine |
|---|---|
| None | 88 |
| No Significant Interference with Subj. Functioning | 18 |
| Significant Interference with Subj. Functioning | 5 |
| Outweigh the Theraputic Effect | 2 |
| Not Assessed | 1 |
The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)
| score on scale | Rotigotine |
|---|---|
| Patient Global Impression (PGI) Item 1 Score | 3.6 ± 1.2 |
The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)
| participants | Rotigotine |
|---|---|
| Marked | 5 |
| Moderate | 25 |
| Minimal | 38 |
| Unchanged or Worse | 44 |
| Missing / Not Done | 2 |
The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)
| participants | Rotigotine |
|---|---|
| No Side Effects | 77 |
| No Significant Interference with Functioning | 24 |
| Significant Interference with Functioning | 6 |
| Outweighing Therapeutic Effect of Trial Medication | 5 |
| Missing / Not Done | 2 |
The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.
| score on scale | Rotigotine |
|---|---|
| Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment | -3.9 ± 13.5 |
Have you used pharmaceutical treatments for your Parkinson's disease before the study?
| participants | Rotigotine |
|---|---|
| yes | 114 |
| no | 0 |
Why did you decide to enter this study?
| participants | Rotigotine |
|---|---|
| Side effects with oral medicine | 14 |
| Oral medicine not effective in controlling sympt. | 21 |
| Taking med. several times a day was not convenient | 71 |
| Other | 40 |
In comparing the patch and previous oral treatments for Parkinson's disease, how satisfied have you been with oral medication / patch?
| participants | Rotigotine |
|---|---|
| Very Dissatisfied with Oral Medication | 3 |
| Dissatisfied with Oral Medication | 11 |
| Neither Satisfied nor Dissatisfied with Oral Med. | 49 |
| Satisfied with Oral Medication | 43 |
| Very Satisfied with Oral Medication | 6 |
| Assessment for Oral Medication Missing / Not Done | 2 |
| Very Dissatisfied with Patch | 9 |
| Dissatisfied with Patch | 28 |
| Neither Satisfied nor Dissatisfied with Patch | 34 |
| Satisfied with Patch | 32 |
| Very Satisfied with Patch | 9 |
| Assessment for Patch Missing / Not Done | 2 |
I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson's disease.
| participants | Rotigotine |
|---|---|
| Strongly Agree | 18 |
| Agree | 34 |
| Neither Agree nor Disagree | 29 |
| Disagree | 28 |
| Strongly Disagree | 3 |
| Not Done / Missing | 2 |
I would prefer applying one 40cm\*\*2 patch over applying two 20cm\*\*2 patches for treatment of my Parkinson's disease.
| participants | Rotigotine |
|---|---|
| Strongly Agree | 17 |
| Agree | 68 |
| Neither Agree nor Disagree | 10 |
| Disagree | 13 |
| Strongly Disagree | 4 |
| Not Done / Missing | 2 |
What aspects do you like the most about the patch?
| participants | Rotigotine |
|---|---|
| Applying the patch once a day | 81 |
| Comfortable to wear | 28 |
| Does not interfere with my normal activities | 61 |
| Do not have to take medicine in public | 56 |
| Provides symptom relief all day | 46 |
| Convenient | 53 |
| Easy to apply | 50 |
| Do not have to remember to take med. during day | 60 |
| Missing / Not Done | 2 |
What aspects do you like the least about the patch? Check all that apply.
| participants | Rotigotine |
|---|---|
| Hard to apply | 11 |
| Hard to remove | 3 |
| Hard to remove the patch from its pouch | 1 |
| Did not stay on for the entire day | 80 |
| Uncomfortable to wear | 27 |
| Not always covered by clothing | 8 |
| Symptom relief did not last all day | 29 |
| Not Done / Missing | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 0/116 (0%) | 45/116 (38.8%) |
| Event | Rotigotine |
|---|---|
| DizzinessNervous system disorders | 7/116 |
| TremorNervous system disorders | 7/116 |
| AstheniaGeneral disorders | 6/116 |
| DyskinesiaNervous system disorders | 6/116 |
| Muscle rigidityMusculoskeletal and connective tissue disorders | 5/116 |
| Dry MouthGastrointestinal disorders | 4/116 |
| BradykinesiaNervous system disorders | 4/116 |
| SomnolenceNervous system disorders | 4/116 |
| Application site pruritusGeneral disorders | 3/116 |
| DyspepsiaGastrointestinal disorders | 2/116 |
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 73 |
| >=65 years | 43 |
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 60.0 ± 10.1 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 69 |
| Male | 47 |
| Region of Enrollment(participants) | Rotigotine |
|---|---|
| Korea, Republic of | 116 |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine